Advertisement
Advertisement
U.S. Markets open in 7 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Pixium Vision SA (ALPIX.PA)

Paris - Paris Delayed Price. Currency in EUR
0.0997+0.0023 (+2.36%)
At close: 05:26PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0974
Open0.0976
BidN/A x N/A
AskN/A x N/A
Day's Range0.0971 - 0.0999
52 Week Range0.0960 - 0.8800
Volume211,572
Avg. Volume253,466
Market Cap5.698M
Beta (5Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.2700
Earnings DateOct 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.70
  • GlobeNewswire

    Pixium Vision announces participation in investor conferences in November and December 2022

    Pixium Vision announces participation in investor conferences in November and December 2022 Paris, France, November 15, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following investor conferences in November and December 2022: LSX's 7th Annual

  • GlobeNewswire

    Pixium Vision announces its cash position at 30 September 2022 and provides an update on its activities

    Pixium Vision announces its cash position at 30 September 2022 and provides an update on its activities Paris, 21 October 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today a cash position of €8.5 million at 30 September 2022 and reports on its key developments. Statement of cash flows summaryIn

  • GlobeNewswire

    Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering

    Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering Distance between the implant and the target cells was stable over the long-term follow-upNo significant thickness changes of the retina after an initial phase of minor thinning Paris, France, October 11, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision sys

Advertisement
Advertisement